Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 588 for “"PDAC"”.
-
Differential DNA hydroxy/methylation analyses for improving prognostic accuracy in localised PDAC and a better understanding of PDAC progression
… prognosis of pancreatic ductal adenocarcinoma (PDAC) remained very poor. The main reasons include the lack of early-stage symptoms and effective screening programmes, leading to delayed clinical presentations, with only 15-20% of patients being diagnosed with localised resectable tumours. …
-
Developing novel immunotherapeutic approaches to pancreatic ductal adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma (PDAC) is a major clinical challenge due to late diagnosis, high metastatic potential, and resistance to conventional therapies. This thesis explores novel immunotherapeutic strategies aimed at improving outcomes in PDAC. <br><br>First, a multiparametric flow …
-
Functional and Molecular Interrogation of Venous Invasion in Human PDAC
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease and is the third leading cause of cancer death in the United States. The basis for this high mortality is mainly due to the high metastatic potential of this cancer. However, little is known about the molecular alterations that drive …
-
Trafficking and function of innate immune cells in PDAC metastasis
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive and lethal form of cancer that has consistently defied efforts to improve patients’ outcome, ow-ing to its rapid progression, early metastasis, and resistance to conventional therapies. Most patients are diagnosed with locally advanced …
-
Mechanismen des nukleären Transports von TRAIL-Rezeptoren in PDAC-Zellen
Das PDAC ist nach wie vor eine Krebserkrankung mit infauster Prognose. Das Zytokin TRAIL steht im Interesse der Tumorforschung, da es in der Lage ist, die Apoptose bei Krebszellen auszulösen und normale Körperzellen zu verschonen. In klinischen Studien erbrachte eine TRAIL-Therapie bisher nicht den …
-
MYELOID MEDIATORS OF IMMUNOSUPPRESSION, METASTASIS, AND DISTANT ORGAN REMODELING IN PDAC
Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal cancers due to aggressive metastatic spread, immunotherapy resistance, and an immunosuppressive tumor immune microenvironment (TiME). Mounting evidence suggests that myeloid cells, including tumor-associated macrophages (TAMs), …
-
Single cell and spatial analysis characterize metabolic DPEP1+ fibroblasts in PDAC
Pancreatic ductal adenocarcinoma (PDAC) is highly malignant and exhibits aggressive progression patterns, resists conventional treatments, and poses significant challenges to patient survival, necessitating urgent research and development of novel therapeutic approaches. Understanding …
-
Using convolutional neural networks to predict NRG1-fusions in PDAC biopsy images
Pancreatic ductal adenocarcinoma (PDAC) is considered the most lethal common cancer, with the highest incidence-to-mortality ratio of any solid tumour. Molecular pathology studies and genomic analyses have improved our understandings of how PDAC develops and progresses, and there has been …
-
FOXJ1, a novel oncosupressor transcription factor in a subgroup of PDAC patients
Pancreatic ductal adenocarcinoma (PDAC) is one of the most prevalent and deadliest cancers. It is predicted to become the second leading cause of cancer mortality within a decade, with an overall 5-year survival of 9%. The existing literature extensively supports the notion that epigenetic …
-
Die Rolle von LGR6 in der Genese des humanen duktalen Pankreaskarzinoms (PDAC)
Das duktale Pankreaskarzinom zählt zu den Tumorerkrankungen mit der schlechtesten Prognose. Dies liegt zum einen an der späten Diagnose im fortgeschrittenen Stadium, sowie der frühen Metastasierung und nicht zuletzt an der Zytostatikaresistenzentwicklung. Vor allem die beiden letzteren …
-
Developing a model of acid-driven evolution for Pancreatic Ductal Adenocarcinoma (PDAC)
<p>Pancreatic ductal adenocarcinomas (PDAC) are characterised by poor prognosis and rising incidence. Their hallmarks include rapid progression, which suggests efficient metabolic reprogramming, and poor response to therapy, corresponding to accelerated somatic evolution. The elevated metabolic …
-
Role of Methyltransferase Like-3 (Mettl3) In Pancreatic Ductal Adenocarcinoma (Pdac) Progression
Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive cancer with about a 10% five-year survival rate. The grim prognostic situation of pancreatic cancer patients underlines the need to identify novel molecular targets. Recent studies have brought to attention, the need to therapeutically …
-
Interplay of TRAIL receptors in PDAC cells: the role of TRAIL-R4
… receptors and the impact of this interplay on PDAC cells behavior.
-
FROM CHECKPOINT TOXICITY TO TUMOR REJECTION: MECHANISTIC INSIGHTS AND THERAPEUTIC CHALLENGES IN PDAC AND BEYOND
… of strategic combination therapy to overcome PDAC’s immune barriers. These studies provide a multi-level guide for discovering the determinants of response and toxicity in immunotherapy. Ultimately, this work highlights the importance of integrative solutions revolving around host immune …
-
Mouse Modeling of Pancreatic Ductal Adenocarcinoma (PDAC); Search for Early Diagnostic Markers and Therapeutic Targets
PDAC is a highly malignant neoplasm that carries a very poor prognosis. PDAC development is a multistage transformation process that involves multiple genetic alterations that include activation of EGFR/HER2 and KRAS, and loss-of-function mutations in INK4A/ARF, p53 and SMAD4. In recent years, …
-
Decoding The Tumor and Immune Microenvironment In Pdac and Breast Cancer By Single Cell Sequencing.
… states of T cell clones from human PDACs into a T cell culture product for adoptive cell therapy. Second, we examined the potential role of radiotherapy in inducing an immune response in hormone receptor positive breast tumors.
-
Sufficiency and Necessity of Tumor-Derived IL6 on Skeletal Muscle in PDAC-Associated Muscle Atrophy
… cancer, pancreatic ductal adenocarcinoma (PDAC), is one of the most fatal cancers worldwide with an 11.5% 5-year survival rate. Cancer cachexia, defined as a loss in skeletal muscle and fat mass that cannot be regained with nutritional supplementation, is a common morbidity that impacts …
Page 1 of 30